AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Company profile
Website
CEO
Karen L. Zaderej
Employees
Incorporated
Location
SEC CIK
Latest filings (excl ownership)
D/A
$5.5M in debt, sold $3M, 13 investors
15 Jun 11
D
$500K in debt, sold $500K, 1 investor
20 May 11
D/A
$3.7M in debt / options, sold $3.7M, 11 investors
12 Jan 11
D
$2M in debt / options, sold $1.1M, 8 investors
25 Jun 10
D
$4.7M in equity / options, sold $3.36M, 8 investors
22 Jan 10
D
$2.62M in debt / options, sold $2.62M, 4 investors
10 Sep 09
REGDEX
Notice of sale of securities
20 Mar 06
Latest ownership filings